Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 4/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2389030 | 0.83 | CSNK2A1 (0.56) | CAMK2DCDK2MAPTCSNK2A1PIK3CA | |
| SCHEMBL16496154 | 0.80 | CAMK2D (0.54) | MAPK14CAMK2DCDK2MAPK13MAPK12 | |
| SCHEMBL2390633 | 0.79 | CDK2 (0.47) | MAPK14CDK2CLK4MAPK13MAPK12 | |
| SCHEMBL6107479 | 0.78 | CSNK2A1 (0.62) | CAMK2DCDK2MAPTCSNK2A1PIK3CA | |
| SCHEMBL14581972 | 0.76 | CAMK2D (0.56) | CAMK2DCDK2CLK4CDC7ROCK2 | |
| SCHEMBL2403389 | 0.75 | CAMK2D (0.52) | MAPK14CAMK2DCDK2CLK4MAPK13 | |
| SCHEMBL2388097 | 0.73 | MAPK1 (0.49) | CDK2MAPK1CCNA2MAPK3 | |
| SCHEMBL2390632 | 0.72 | CAMK2D (0.50) | MAPK14CAMK2DCDK2MAPK13MAPK12 | |
| SCHEMBL6106440 | 0.71 | MAPT (0.55) | CAMK2DCDK2CLK4CDC7ROCK2 | |
| SCHEMBL2390628 | 0.71 | CSNK2A1 (0.57) | CAMK2DCDK2MAPTCSNK2A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205086-B1 | FUNGICIDAL HETEROCYCLIC AMINES | DU PONT (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20110301123-A1 | Fungicidal Heterocyclic Amines | E.I. DU PONT NEMOURS AND COMPANY (US) | 2011-12-08 | — | — | US | disclosed |
| US-8026359-B2 | Fungicidal heterocyclic amines | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100267729-A1 | FUNGICIDAL HETEROCYCLIC AMINES | E.I. DU PONT DE NEMOURS AND COMPANY (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-2205086-A2 | FUNGICIDAL HETEROCYCLIC AMINES | E. I. du Pont de Nemours and Company (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009061761-A2 | FUNGICIDAL HETEROCYCLIC AMINES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267729-A1 | FUNGICIDAL HETEROCYCLIC AMINES | PRMT9, MAOB, CYP2C9 | MAPK14 3681/4885CAMK2D 4032/4885CDK2 2324/4885 |
| US-20110301123-A1 | Fungicidal Heterocyclic Amines | PRMT9, MAOB, CYP2C9 | MAPK14 3681/4885CAMK2D 4032/4885CDK2 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.